Testagen is a bioregulator peptide targeting testicular tissue — the primary site of testosterone synthesis and spermatogenesis in men. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Testagen activates gene expression in Leydig cells (testosterone-producing) and Sertoli cells (spermatogenesis-supporting) that progressively silences with age — the epigenetic contribution to the androgen decline that begins in men's third and fourth decades and accelerates significantly after 50.

Testosterone is the master anabolic hormone of the male body: governing muscle mass, bone density, libido, red blood cell production, mood, cognitive function, and metabolic efficiency. Age-related testosterone decline (andropause) is one of the most consequential hormonal changes in male aging — yet unlike female menopause, it occurs gradually and is often attributed to "normal aging" rather than recognized as a treatable or addressable endocrine change. The epigenetic component of this decline — progressive silencing of steroidogenic genes in Leydig cells — is exactly what Testagen targets.

Testagen's peptide sequence penetrates Leydig cell and Sertoli cell nuclei and binds to histone-DNA complexes, reactivating transcription of testicular functional genes. In Leydig cells, these include the steroidogenic enzyme genes (StAR, CYP11A1, 3β-HSD, CYP17A1, 17β-HSD) that constitute the testosterone synthesis pathway, LH receptor genes enabling pituitary-gonadal axis signaling, and anti-apoptotic factors maintaining Leydig cell viability. In Sertoli cells, Testagen activates genes for androgen-binding protein (ABP), inhibin, FSH receptor, and structural support proteins required for spermatogenesis.

Research from the Khavinson group demonstrates measurable effects on testicular function. In aging animal models, Testagen treatment increased testicular weight (a proxy for Leydig cell and seminiferous tubule mass), elevated serum testosterone levels compared to untreated aging controls, improved histological markers of spermatogenesis quality, and reduced apoptotic markers in testicular cell populations. The testosterone elevation mechanism is distinct from exogenous testosterone administration — rather than replacing testosterone, Testagen restores the cellular machinery that produces testosterone endogenously, maintaining pituitary-gonadal feedback and avoiding the testicular atrophy and fertility suppression that accompany exogenous testosterone.

Human clinical applications in the Khavinson group's work have focused on aging men with documented testosterone decline and hypogonadal symptoms, fertility concerns in aging males, and preventive protocols for men seeking to maintain endocrine health. Outcomes include improvements in serum testosterone levels, FSH/LH axis normalization, improvements in male sexual health parameters, and subjective improvements in energy, libido, and mood consistent with testosterone restoration.

The key distinction from testosterone replacement therapy (TRT): Testagen works upstream at the epigenetic level to restore endogenous testosterone production, preserving natural pulsatility, HPG axis feedback, and fertility — outcomes impossible with exogenous testosterone supplementation. Protocol: 2mg/day for 10 consecutive days, subcutaneous injection, 2–4 courses per year.